Robert Ragusa Sells 123,502 Shares of GRAIL (NASDAQ:GRAL) Stock

GRAIL, Inc. (NASDAQ:GRAL) CEO Robert Ragusa sold 123,502 shares of the company’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the sale, the chief executive officer directly owned 518,582 shares in the company, valued at approximately $25,887,613.44. The trade was a 19.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

GRAIL Stock Down 4.1%

Shares of GRAL opened at $45.63 on Friday. GRAIL, Inc. has a fifty-two week low of $22.30 and a fifty-two week high of $118.84. The firm’s 50 day moving average price is $63.91 and its 200 day moving average price is $79.53. The company has a market cap of $1.87 billion, a P/E ratio of -4.08 and a beta of 4.62.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) EPS for the quarter, topping the consensus estimate of ($3.33) by $0.89. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%. The company had revenue of $43.60 million during the quarter, compared to analysts’ expectations of $43.33 million. Research analysts forecast that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. N.E.W. Advisory Services LLC acquired a new position in shares of GRAIL in the 4th quarter valued at $26,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of GRAIL in the 4th quarter valued at $28,000. Elyxium Wealth LLC acquired a new position in shares of GRAIL in the 4th quarter valued at $31,000. Comerica Bank boosted its holdings in shares of GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after buying an additional 173 shares in the last quarter. Finally, Intesa Sanpaolo S.p.A. acquired a new position in shares of GRAIL in the 4th quarter valued at $44,000.

Trending Headlines about GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Analyst consensus remains constructive: Street coverage still shows an average rating of “Moderate Buy” with a consensus price target around $72.83, implying meaningful upside from current levels. Article Title
• Neutral Sentiment: Mizuho initiated coverage with a “neutral” rating and a $58 price target (roughly mid‑teens to low‑20s % upside vs. current quoted levels); the call is cautious and reflects uncertainty rather than outright bullishness. Article Title
• Neutral Sentiment: Piper Sandler also initiated coverage with a “neutral” rating and a $54 price target, signaling analyst caution and limited near‑term conviction. Article Title
• Negative Sentiment: Reported study setback: coverage initiation notes reference a recent study disappointment that prompted the neutral stances — clinical execution and near‑term data risk are now front and center for investors. Article Title
• Negative Sentiment: Insider selling by senior management: CEO, President and CFO sold sizable blocks on April 8 (CEO ~123,502 shares; President ~61,665; CFO ~45,806), materially reducing their holdings — a strong negative signal to the market and a likely contributor to downward pressure. Article Title

Wall Street Analyst Weigh In

Several research firms have commented on GRAL. Mizuho began coverage on shares of GRAIL in a report on Friday. They set a “neutral” rating and a $58.00 price target for the company. Canaccord Genuity Group lowered their price target on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a report on Friday, February 20th. Guggenheim lowered their price target on shares of GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a report on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Finally, Morgan Stanley lowered their price target on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $68.63.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.